Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China

A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection

This study will evaluate the safety and immunogenicity of booster doses of the two vaccines used to prevent Haemophilus influenzae type b infections in children 12-18 months of age.

Inclusion Criteria:

• Toddlers 12-18 months of age who have previously participated in study M37P2.

Exclusion Criteria:

• Prior Hib booster administration.
• History of serious reaction(s) following vaccination.
• Vaccination within 14 days of study vaccination.
• Known or suspected immune impairment.
• For additional entry criteria please refer to the protocol.